A Retrospective Claims Analysis of Bronchodilator Monotherapy Versus Dual Bronchodilator Fixed-Dose Combination in Patients with COPD

Combination bronchodilator therapy in COPD.

Bronchodilator responsiveness in patients with COPD.

The degree of acute improvement in spirometric indices after bronchodilator inhalation varies among chronic obstructive pulmonary disease (COPD) patients, and depends upon the type and dose of bronchodilator and the timing of administration. Acute bronchodilator responsiveness at baseline was examined in a large cohort of patients with moderate-to-very-severe COPD participating in the Understan...

Which bronchodilator in COPD?

Which bronchodilator in COPD? There have been few developments in the pharmacotherapy of chronic obstructive pulmonary disease (COPD) that have been so eagerly awaited as that of a long acting anticholinergic compound. For the fi rst time there was a treatment available which was designed with COPD specifi cally in mind. This was not an asthma treatment that had been tried in COPD with more hop...

Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands

PURPOSE The fixed-dose dual bronchodilator combination (FDC) of tiotropium and olodaterol showed increased effectiveness regarding lung function and health-related quality of life in patients with chronic obstructive pulmonary disease (COPD) compared with the use of its mono-components. Yet, while effectiveness and safety have been shown, the health economic implication of this treatment is sti...

Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study

INTRODUCTION This study aimed to characterize patients with chronic obstructive pulmonary disease (COPD) newly prescribed a long-acting bronchodilator (LABD), and to assess changes in medication over 24 months. METHODS A cohort of patients with COPD aged ≥40 years newly prescribed an LABD between January 1, 2007 and December 31, 2009 were identified from the Truven Marketscan(®) Commercial Da...